Cargando…

Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma

BACKGROUND: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea. METHODS: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical cente...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Byung Woog, Sohn, Sang Kyun, Moon, Joon Ho, Chae, Yee Soo, Kim, Jong Gwang, Lee, Soo Jung, Kim, Won Seog, Lee, Je-Jung, Lee, Se Ryeon, Park, Keon Uk, Lee, Ho Sup, Lee, Won Sik, Won, Jong-Ho, Park, Moo-Rim, Kwak, Jae-Yong, Kim, Min Kyoung, Kim, Hyo Jung, Oh, Sung Yong, Kang, Hye Jin, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974951/
https://www.ncbi.nlm.nih.gov/pubmed/24724062
http://dx.doi.org/10.5045/br.2014.49.1.15
_version_ 1782310071852597248
author Kang, Byung Woog
Sohn, Sang Kyun
Moon, Joon Ho
Chae, Yee Soo
Kim, Jong Gwang
Lee, Soo Jung
Kim, Won Seog
Lee, Je-Jung
Lee, Se Ryeon
Park, Keon Uk
Lee, Ho Sup
Lee, Won Sik
Won, Jong-Ho
Park, Moo-Rim
Kwak, Jae-Yong
Kim, Min Kyoung
Kim, Hyo Jung
Oh, Sung Yong
Kang, Hye Jin
Suh, Cheolwon
author_facet Kang, Byung Woog
Sohn, Sang Kyun
Moon, Joon Ho
Chae, Yee Soo
Kim, Jong Gwang
Lee, Soo Jung
Kim, Won Seog
Lee, Je-Jung
Lee, Se Ryeon
Park, Keon Uk
Lee, Ho Sup
Lee, Won Sik
Won, Jong-Ho
Park, Moo-Rim
Kwak, Jae-Yong
Kim, Min Kyoung
Kim, Hyo Jung
Oh, Sung Yong
Kang, Hye Jin
Suh, Cheolwon
author_sort Kang, Byung Woog
collection PubMed
description BACKGROUND: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea. METHODS: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL. RESULTS: The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS. CONCLUSION: Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.
format Online
Article
Text
id pubmed-3974951
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
record_format MEDLINE/PubMed
spelling pubmed-39749512014-04-10 Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma Kang, Byung Woog Sohn, Sang Kyun Moon, Joon Ho Chae, Yee Soo Kim, Jong Gwang Lee, Soo Jung Kim, Won Seog Lee, Je-Jung Lee, Se Ryeon Park, Keon Uk Lee, Ho Sup Lee, Won Sik Won, Jong-Ho Park, Moo-Rim Kwak, Jae-Yong Kim, Min Kyoung Kim, Hyo Jung Oh, Sung Yong Kang, Hye Jin Suh, Cheolwon Blood Res Original Article BACKGROUND: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea. METHODS: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL. RESULTS: The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS. CONCLUSION: Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2014-03 2014-03-24 /pmc/articles/PMC3974951/ /pubmed/24724062 http://dx.doi.org/10.5045/br.2014.49.1.15 Text en © 2014 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kang, Byung Woog
Sohn, Sang Kyun
Moon, Joon Ho
Chae, Yee Soo
Kim, Jong Gwang
Lee, Soo Jung
Kim, Won Seog
Lee, Je-Jung
Lee, Se Ryeon
Park, Keon Uk
Lee, Ho Sup
Lee, Won Sik
Won, Jong-Ho
Park, Moo-Rim
Kwak, Jae-Yong
Kim, Min Kyoung
Kim, Hyo Jung
Oh, Sung Yong
Kang, Hye Jin
Suh, Cheolwon
Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
title Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
title_full Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
title_fullStr Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
title_full_unstemmed Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
title_short Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
title_sort clinical features and treatment outcomes in patients with mantle cell lymphoma in korea: study by the consortium for improving survival of lymphoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974951/
https://www.ncbi.nlm.nih.gov/pubmed/24724062
http://dx.doi.org/10.5045/br.2014.49.1.15
work_keys_str_mv AT kangbyungwoog clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT sohnsangkyun clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT moonjoonho clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT chaeyeesoo clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT kimjonggwang clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT leesoojung clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT kimwonseog clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT leejejung clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT leeseryeon clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT parkkeonuk clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT leehosup clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT leewonsik clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT wonjongho clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT parkmoorim clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT kwakjaeyong clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT kimminkyoung clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT kimhyojung clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT ohsungyong clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT kanghyejin clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma
AT suhcheolwon clinicalfeaturesandtreatmentoutcomesinpatientswithmantlecelllymphomainkoreastudybytheconsortiumforimprovingsurvivaloflymphoma